Contrast agents (CAs) are one of the medications most used by interventional pain practitioners. They are used to confirm target, to distinguish different surrounding tissues, and to deliver adequate medication to specific areas of pathology. The high tolerance of modern CAs has been achieved through successive developments in chemical pharmacologic technology. Different CAs vary greatly in their chemical properties and toxic effects.
Introduction
Without doubt, fluoroscopy and contrast media have made invasive pain treatment much safer. It is very important to correctly interpret fluoroscopic images and different contrast pattern flow, to perform safe and adequate interventional pain treatment techniques. Unfortunately, fluoroscopy can sometimes provide a false sense of security when fluoroscopic images are not properly interpreted. Contrast agents (CAs) are among the most used medications in interventional pain treatment along with local anesthetics and corticosteroids. 1 It is estimated that approximately 75 million doses of intravenous (iv) CAs are administered worldwide each year. 2 They serve no therapeutic purpose; their role is merely diagnostic by helping the practitioner to better distinguish different anatomical structures, visualize pain target, recognize vascular uptake, and interpret contrast pattern flow. 3 They also help avoid false-negative results in diagnostic blocks, making them more accurate. 4 Although they are used in smaller and, thus, safer doses than for radiological diagnostic purposes, severe allergic reactions may occur ( Table 1) .
Mode of action of CAs
Different degrees of attenuation of x-ray beams by different body tissues are transformed into a black-and-white scale. The degree of attenuation is complex, but one of the major variables is the number of electrons with which the beam can interact in its path. Where there is a difference between densities of 2 structures, the outlines of the structures can be visualized with the help of CAs. The spinal cord and nerves cannot be seen using conventional x-rays, but they can be made visible by injecting CAs in the surrounding tissues, with a presumable pattern flow. It also helps to differentiate intrathecal, epidural, and subdural spaces (though this can sometimes be very challenging) and intravascular and intra-arterial flow and to perform discographies and arthrograms. It is very important to adequately interpret the CA flow and dispersal pattern. See Figures 1-6 for different contrast flow patterns.
Clinical pharmacology
All CAs have a similar chemical structure, with a tri-iodinated benzene ring. There are mainly 2 kinds of CAs: iodinated and gadolinium-based. The former are the most broadly used CAs, whereas gadolinium-based CAs are used for iodinated allergic patients. 5 Iodinated CAs can be divided into ionic and nonionic 6 based on water solubility (ionic CAs dissociate into ions and cations in blood) and charge of the iodinated molecule. They can be monomers or dimers depending on their molecular structure. They can also be classified based on osmolality compared with blood serum into low osmolal, iso-osmolal, and hyperosmolal. 7 Ionic CAs are generally monomers and hyperosmolal, whereas nonionic CAs are generally isosmolal, more viscous, and more hydrophilic. 8 Each of the 4 types of ionic CAs has different properties, clinical uses, and toxicity profiles. Only CAs specifically formulated for neural tissue can be used in pain treatment, as there is a high risk on direct administration to the neural tissue. 9 Nonionic CAs are more hydrophilic, so their subarachnoid and iv toxicity is greatly reduced. They do not combine with proteins or macromolecules and are thus considerably less toxic than ionic CAs are. All myelography procedures as well as procedures with injection of CAs around the neural tissue are best performed with nonionic agents. 1 Although interventional pain physicians do not perform myelography, inadvertent intrathecal administration of CAs can occur during interventional spinal procedures. 10 For this reason, only CAs that are not neurotoxic can be used. Ionic CAs are neurotoxic, so they are contraindicated in spinal procedures. 11, 12 All CAs have low protein binding. When administered through the perineural, intra-articular, or intratissue approach, they are absorbed via the lymphatic system. All CAs are eliminated unchanged by the kidneys via glomerular filtration with no significant tubular reabsorption. 13 The elimination half-life of most agents falls within the range of 90-120 minutes in patients with normal renal function, but elimination can be delayed for up to several weeks in patients with impaired renal function.
Adverse reactions to CAs
Adverse reactions to CAs can be classified into general and organ specific. 14 General adverse reactions are subclassified into acute and delayed reactions 15 depending on time of onset. Acute reactions can be mild (nausea, mild vomiting, urticarial, and itching), moderate (severe vomiting, marked urticarial, bronchospasm, facial-laryngeal edema, and vasovagal reaction), and severe (hypotensive shock, respiratory arrest, cardiac arrest, and convulsions), while delayed reactions are those that occur 1 hour to 1 week after the procedure. 15 Delayed severe reactions are very rare; the underlying pathophysiological mechanism is thought to be T-cell mediated. 16 Adverse reactions are also classified into chemotoxic and hypersensitivity reactions depending on the pathophysiological mechanism. 17 Chemotoxic reactions depend on chemical properties (they are due to direct molecular toxicity) and include vasovagal reactions, seizures, arrhythmias, and organ-specific toxicity (cardiac, neurologic, and renal toxicity). In the low-volume administration used for most image-guided pain management interventions, chemotoxic reactions are highly unlikely. Hypersensitivity reactions are idiosyncratic or pseudoallergic reactions. They are usually unpredictable, not dose dependent, and involve the release of biological mediators such as histamine, serotonin, prostaglandins, bradykinin, leukotrienes, adenosine, and endothelin. Contrast media can activate-directly or indirectly-the complement, coagulation, fibrinolytic, and kinin cascades. Although the symptoms of allergiclike reactions resemble those of hypersensitivity reactions, the exact mechanism is unknown and does not appear to result from an antigenantibody interaction in most cases, as antibodies to CAs have not been consistently demonstrated. 18, 19 Iodine allergy usually refers to a history of adverse reaction to CAs or sometimes a contact dermatitis by povidoneiodine 20 ( Table 2) .
Incidence of adverse reactions
The incidence of adverse reactions, which varies depending on the type of CA, is lower with low osmolal nonionic agents. 21 We focus on nonionic CAs, as they are the ones used in pain treatment. The risk of toxic reactions to nonionic CAs ranges from 0.04%-3%. 21 Acute general mild reactions occur in 3%, moderate reactions in 0.2%-0.4%, and severe reactions in 0.04% of patients. 18, 22 Deaths due to CAs are rare, the risk is 1:170,000. 18 A report of 48 deaths due to CAs (not in patients undergoing pain treatment) revealed that 58% of deaths were due to renal failure, 19% to anaphylaxis, 10% to cardiac arrest, 8% to respiratory failure, and 4% to cerebral hypoxia. 23 The prevalence of adverse reactions to nonionic CAs is 5%. 24 
Risk factors associated with adverse reactions
The risk of adverse reactions to CAs increases in 20-to 50-year-old individuals. Reactions are less frequent after 50 years of age but tend to be more severe in the elderly. 25 History of previous adverse reactions, allergy, asthma, dehydration, pre-existing renal disease, anxiety, β-blockers (do not impart a direct risk, but they may hinder treating adverse for an interventional pain treatment reported a previous adverse reaction to CAs, which exceeds the incidence of reported adverse reactions. One of the most widely propagated myths is that a link exists between patient-reported shellfish allergy and increased risk of allergic reaction to iodinated CAs. There is no evidence that patients reporting allergy to shellfish have a higher risk of reaction to iodinated CAs when compared with patients with any other allergy. Shellfish allergies are not related to iodine: most are due to tropomyosin. 27 
CAs warning
All patients who are programed to receive CAs must be warned about the risks of possible adverse reactions in the written informed consent. Furthermore, they should be specifically asked if they have had a previous adverse reaction to CAs and a detailed history of allergies to other substances or medication. They should be advised to stay on premises at least 30 minutes after the procedure and then be discharged with an accompanying person.
Prevention of adverse reactions
Routine hypersensitivity skin tests before CAs administration are not recommended, because they entail certain risk and do not predict the real danger (a negative result does not mean a dangerous reaction cannot happen). 28 If the patient reports a previous adverse reaction, the ENDA questionnaire may be useful in obtaining information regarding the patient's history and clinical manifestations. 29 Pretreatment guidelines have been developed for patients who are at high risk. 30 Only patients with a history of moderate or severe adverse reactions to CAs should be premedicated. No randomized control trials have demonstrated protection from life-threatening adverse events. 31, 32 A combination of corticosteroids (prednisone or methylprednisolone) and H1-blockers (diphenhydramine) with or without H2-blockers (cimetidine) has been shown to be beneficial in preventing adverse reactions to Table 2 -Classification of adverse reactions to contrast agents.
CAs. 33 If the patient is taking β-blockers, administration should be discontinued, unless contraindicated by the medical situation. Early recognition and management of adverse reactions is invaluable in preventing life-threatening reactions. It is important not to leave patients alone for at least 20 minutes after contrast media injection, as most severe and fatal reactions occur within 20 minutes of injection of the contrast medium. 34 To prevent any adverse reaction, as a rule, the pain practitioner should always administer the lowest dose, concentration, and number of injections needed to obtain the required diagnostic clinical information. It is also very important to take into account that a previous uneventful CA injection does not ensure the safety of the current contrast medium injection. There must always be a system available to call for experienced medical assistance. It is also very important to avoid storing the CAs in the same place as in other specialties. Confusion and mismatching of neurotoxic CAs are possible, so storage in different places and adequate labeling are mandatory.
Although only small doses of CAs are used in pain treatment, it is important to limit the iodine dose and never reach a 3-g dose of iodine per day, which is the maximum accepted dose for an adult in myelography procedures. 35 In patients who are at risk of CA-associated nephrotoxicity, hydration along with prophylactic administration of N-acetylcysteine (600 mg orally twice daily) 36 ; vitamin E (350 mg/d of α-tocopherol or 300 mg/d of γ-tocopherol) 37 ;
statins (atorvastatin 80 mg 12 hours before intervention with another 40 mg before procedure, followed by long-term atorvastatin treatment of 40 mg/d) 38 ; and nebivolol, a third-generation beta-adrenergic blocker with vasodilator and antioxidant properties (5-mg nebivolol every 24 hours for 4 days) 39 has shown to prevent such risk (in vascular angiography setting). Despite premedication, no intervention completely eliminates the risk of an immediate hypersensitivity reaction. 40 Therefore, the pain practitioner must be prepared to treat immediate reactions even when preventive steps have been taken (Table 3) .
Treatment of adverse reactions
An emergency cart and all medication and facilities for treating life-threatening conditions should always be available and regularly checked (oxygen, adrenaline 1:1000, atropine, beta-2-agonist-metered dose inhaler, iv fluids-normal saline or Ringer solution, anticonvulsive drugs such as diazepam and corticosteroids, and airway management devices). All members of the pain treatment team should be prepared and trained for any incidence. All patients should be adequately monitored following the American Society of Anesthesiologists Practice Guidelines, 41 but pulse oximetry and blood pressure should be mandatory. Conscious sedation is recommended in interventional procedures, as talking to the patient is the best monitoring method: the patient must be awake so as to report any impending misadventure. Deep sedation is not routinely recommended and has been associated with an increased risk of adverse events. 42 Acute CA reactions occur within an hour of use. Vagal reaction is treated by raising the patient's legs (the Trendelenburg position) and by hydrating with iv fluids and 0.6 mg of iv atropine. Depending on the patient's response to the initial dose, additional doses may need to be administered. If iv access cannot be obtained or is lost, some drugs can also be administered intramuscularly (im). Hypotension, if observed, should be treated by placing the patient in the Trendelenburg position and by administration of oxygen via mask at 6-10 L/min, iv fluids, 5 mg of ephedrine iv, and, if unresponsive, 0.5 mL of adrenaline (1:1000), and this should be repeated as needed.
Mild reactions: They include nausea, vomiting, limited urticaria, and pallor and are usually self-limiting and require only supportive treatment and observation.
Moderate reactions: They must be treated promptly. Nausea and vomiting can be treated with antiemetic drugs such as 12.5 mg of prochlorperazine maleate diluted to 10 mL with normal saline iv over 2 minutes or 4 mg of ondansetron iv, droperidol, or metoclopramide. Urticaria should be treated Note: Intravenous corticosteroids have not been shown to be effective when administered less than 4 hours before contrast agent injection. 2 0 1 4 ) 6 5 -7 5 with appropriate H1-antihistamine such as 4-8 mg of chlorpheniramine maleate orally or 10-20 mg iv slowly over 2 minutes. Drowsiness and hypotension may occur. If generalized or severe urticaria occurs, in addition to H1-antihistamine, consider administrating adrenaline at a dose of 1:1000, 0.1-0.3 mL (0.1-0.3 mg), iv or im, and repeat as needed. Laryngeal edema and bronchospasm should be treated with oxygen mask (6-10 L/min), nebulization with salbutamol (5 mg in 2 mL of saline), and 0.5 mL (0.5 mg) of adrenaline (1:1000) iv or im.
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Severe adverse reactions: They include generalized anaphylactoid reaction, hypotensive shock, respiratory arrest, and cardiac arrest and convulsions and should be treated aggressively. Generalized anaphylactoid reaction requires immediate call for help. 43 Airway suctioning should be performed if needed. Place the patient in the Trendelenburg position. Administer oxygen via mask (6-10 L/min) or intubate the patient if low saturation is maintained. Glucocorticoids administered during emergency management are not believed to affect acute symptoms. They may be beneficial in preventing or reducing the severity of delayed symptoms, although this has never been conclusively demonstrated. 44 Administer 0.5 mg (iv or im) of adrenaline (1:1000), repeat as needed; iv fluids (normal saline or Ringer solution); and 25-50 mg of H1-blocker diphenhydramine iv. 45 If the airway cannot be protected, intubate the patient. Early elective intubation is also recommended for those who develop hoarseness, lingual edema, oropharyngeal edema, or stridor. Hypotensive shock should be treated with iv fluids (normal saline or Ringer solution) along with vasopressors: 0.5 mg of adrenaline (1:1000) iv or im, repeat as needed, or 5-10 mg of ephedrine bolus, and repeat as needed. If nonresponsive to epinephrine (patients on β-blockers), iv glucagon (1-5 mg) can be administered. Respiratory arrest should be treated with airway management and respiratory support. Cardiac arrest should be treated with the advanced cardiac life support protocol. Convulsions should be treated with anticonvulsive drugs. If any patient is progressing toward circulatory collapse, emergency transport to a critical care unit should be arranged and advanced cardiac life support protocols should be immediately instituted.
If an immediate hypersensitivity reaction to CAs occurs, after the support measures, some laboratory tests can be performed to rule out if the reaction was a truly anaphylactic reaction. Serum or urine test results obtained as soon as possible after the reaction may show elevations of tryptase or histamine levels released from activated mast cells 46 ( Table 4) .
Other adverse reactions
Iodine content in CAs can presumably induce thyroid dysfunction 47 (transiently subclinical hypothyroidism) even in euthyroid patients. The TSH reaction seems to depend on the pre-existing state of thyroid function 48 and CA-induced nephropathy. 49 Although not frequently at the small doses used in pain treatment, they have to be taken into account. Some rare reactions have been described after administration of iodine CAs, such as iodide mumps. 50 Other idiosyncratic reactions to high doses of iodine (not in patients undergoing pain treatment) with an unknown pathomechanism have been reported, such as acneiform eruptions, iododerma, [51] [52] [53] leukocytoclastic vasculitis, 54 dermatitis herpetiformis or Duhring disease, 55 bullous pemphigoid, 56 and hypocomplementemic vasculitis. 57 
Cytotoxicity of CAs
Despite being a controversial tool, CAs have been used to perform discography procedures, in which CAs are introduced, with or without local anesthetics, in the intervertebral disc to alleviate or reproduce spinal pain and obtain a discogram. 58, 59 CAs, along with local anesthetics, 60 have been shown to be cytotoxic to intervertebral disc cells (IVDCs) in in vitro studies. 61 CAs have shown to be less cytotoxic to
IVDCs than local anesthetics are; and iopamidol showed to be more toxic to IVDCs than iohexol did.
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Effects of CAs on platelet aggregation and degranulation
Nonionic CAs have been shown to affect platelet aggregation and degranulation. Iopamidol increases aggregation and degranulation of platelets, which could contribute to thromboembolic complications, although these effects have only been shown in vitro, the real effect in clinical practice is unknown.
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Which CA should be used?
As a rule, ionic CAs should not be used for interventional pain procedures. For procedures where the chance of injection into the theca sac is low (medial branch block or radiofrequency denervation, intra-articular facet block, and sacroiliac joint block or radiofrequency denervation) most nonionic CAs can be used. Whenever there is a chance of injection into the dural sac (interlaminar or transforaminal epidural injection, adhesiolysis technique, spinal cord stimulation implant, and intrathecal drug delivery implant), only agents approved for intrathecal use can be used. 64 All CAs should be specifically checked for intrathecal use approval and labeled accordingly. Some nonionic CAs are not approved for intrathecal use, so careful attention must be given. Only low osmolality, watersoluble, nonionic dimers are less neurotoxic and are accepted for intrathecal use. 65 Iopamidol (300-M) and iohexol are nonionic, water-soluble, contrast media that are frequently used in myelography. Despite their low neurotoxic effect, seizures can occur, as described by some authors. [66] [67] [68] [69] Incidence appears to be higher in procedures in the cervical area. 67 Whenever CAs are used, the neurotoxic effect (possibility of seizures), even with CAs approved for intrathecal use, must be taken into account, and benzodiazepines should be at hand.
67 Patients with confirmed allergy to iodine nonionic CAs
Routine skin testing in patients with past hypersensitivity reactions to CAs is not an effective means of preventing recurrent reactions, 70 but consensus is lacking about whether it may be helpful in evaluating patients with previous severe reactions. 71 Gadolinium-based chelates are an alternative for patients with confirmed adverse reactions to iodinated CAs. 72 Adverse reactions to gadolinium have been reported 73 ; however, the incidence is very low. 74 A retrospective study showed that patients with previous iodinated CA adverse reactions underwent spinal procedures with gadolinium without any adverse reactions. 75 
Conclusions
CAs used in interventional pain procedures can be a source of possible adverse reactions, some of which can be life threatening. Patients who have experienced an adverse reaction to CAs are at an increased risk for a recurrent reaction with the next exposure. Prophylactic measures to prevent them are mandatory. If an adverse event in relation to CAs occurs, immediate and proper treatment should be provided, and the event should be properly documented. The most common adverse events to CAs are hypersensitivity reactions that are idiosyncratic, not dose related. Chemotoxic, dose-related reactions can also occur, but they are less common in interventional pain treatment. Water-soluble, low osmolar, nonionic CAs are should be used in interventional pain treatment. They should be approved for intrathecal use, as described in the label instructions. The maximum dose of nonionic CA is 3 g. All staff members should be prepared to treat life-threatening hypersensitivity reactions to CAs. Gadolinium could be used as an alternative to iodine CAs in the presence of documented allergy.
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